Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Duality Biotherapeutics, Inc. ( (HK:9606) ) is now available.
Duality Biotherapeutics, Inc. has announced that its key product, DB-1310, an antibody-drug conjugate targeting HER3, has received Fast Track Designation from the U.S. FDA. This designation is intended to expedite the development and review of drugs that treat serious conditions and address unmet medical needs. The designation for DB-1310 is specifically for treating advanced non-squamous non-small cell lung cancer in patients with specific genetic mutations who have progressed after other treatments. This development could enhance Duality Biotherapeutics’ position in the ADC market and potentially provide a new treatment option for patients with limited alternatives.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$270.34 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics is a significant entity in the global antibody-drug conjugate (ADC) sector, focusing on the development of innovative treatments for cancer and autoimmune diseases.
Average Trading Volume: 377,452
For a thorough assessment of 9606 stock, go to TipRanks’ Stock Analysis page.